How much is the latest price of a box of pemetinib/pemetinib targeted drug in 2025

Pemigatinib is an oral, selective fibroblast growth factor receptor (FGFR) inhibitor that is suitable for the treatment of cancer patients with certain genetic mutations. It was first developed by Incyte and received accelerated approval from the US FDA. It is mainly used to treat adult patients with locally advanced or metastatic cholangiocarcinoma (CCA) with FGFR2 fusion or rearrangement, especially when at least one previous systemic treatment regimen has failed. In addition, the drug is also approved for the treatment of myeloproliferative tumors carrying FGFR1 rearrangements, including some refractory or relapsed myeloid or lymphoid system tumors. Pemetinib blocks the growth and spread of cancer cells by inhibiting the activity of the FGFR signaling pathway, and has certain advantages in targeted therapy.

In the domestic market, pemetinib is marketed as "pemetinib tablets", with common specifications of 4.5 mg × 14 tablets and 9 mg × 14 tablets. However, due to its short time on the market, it has not yet been included in the national medical insurance directory, which makes patients face a high financial burden when taking the medicine. Depending on the specifications, the price range of pemetinib in mainland China ranges from approximately RMB 20,000 to RMB 50,000 per box. In overseas markets, especially in Europe and the United States, the price of 13.5 mg × 14 tablets is even as high as more than 70,000 yuan. The specific selling price is also affected by changes in international exchange rates. In order to reduce the cost of medication, some patients turn to generic drugs, such as the generic version of pemetinib produced by Lucius Pharmaceuticals in Laos. The specification is 4.5 mg × 14 tablets. Each box may be sold for only about RMB 700, which greatly lowers the threshold for medication.

Although generic drugs are basically the same as the original drugs in terms of ingredients and mechanism of action, patients are still advised to conduct an evaluation under the guidance of a professional doctor before choosing to use them to ensure the safety and effectiveness of the treatment.

Reference materials:https://go.drugbank.com/drugs/DB15102